ALX Oncology Announces Results From Phase 1b/2 Trial Of Evorpacept In Combination With Zanidatamab Will Be Presented At The San Antonio Breast Cancer Symposium 2024
Portfolio Pulse from Benzinga Newsdesk
ALX Oncology announced that results from its Phase 1b/2 trial of evorpacept in combination with Jazz Pharmaceuticals' zanidatamab for HER2-positive and HER2-low metastatic breast cancer will be presented at the San Antonio Breast Cancer Symposium in December 2024.
November 01, 2024 | 10:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ALX Oncology's announcement of trial results presentation at SABCS 2024 could boost investor confidence in its cancer treatment pipeline, potentially impacting stock prices positively.
The announcement of the presentation of trial results at a major symposium suggests progress in ALX Oncology's cancer treatment pipeline, which could enhance investor confidence and positively impact stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90